Revvity (NYSE:RVTY) Upgraded by Royal Bank Of Canada to “Hold” Rating

Royal Bank Of Canada upgraded shares of Revvity (NYSE:RVTY) to a hold rating in a research note issued to investors on Tuesday,Zacks reports.

Several other brokerages also recently commented on RVTY. JPMorgan Chase & Co. cut their target price on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Evercore reissued an “outperform” rating on shares of Revvity in a research note on Wednesday, August 5th. Wolfe Research initiated coverage on Revvity in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Weiss Ratings raised Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. Finally, Sanford C. Bernstein assumed coverage on Revvity in a report on Friday, June 26th. They issued a “market perform” rating and a $115.00 target price on the stock. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat, Revvity has an average rating of “Hold” and a consensus price target of $110.58.

Revvity Trading Down 1.6%

Shares of NYSE RVTY opened at $126.59 on Tuesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity has a 52-week low of $81.22 and a 52-week high of $130.07. The firm has a 50 day moving average price of $115.22 and a two-hundred day moving average price of $101.55. The stock has a market cap of $14.13 billion, a P/E ratio of 60.28, a price-to-earnings-growth ratio of 2.34 and a beta of 1.09.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. During the same quarter in the previous year, the business earned $1.18 earnings per share. Revvity’s revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts forecast that Revvity will post 5.36 EPS for the current year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity’s dividend payout ratio is 13.33%.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System boosted its position in shares of Revvity by 19.8% during the 1st quarter. California State Teachers Retirement System now owns 133,809 shares of the company’s stock valued at $11,723,000 after purchasing an additional 22,075 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Revvity in the second quarter worth approximately $78,766,000. Corient Private Wealth LLC lifted its stake in Revvity by 985.0% in the fourth quarter. Corient Private Wealth LLC now owns 126,568 shares of the company’s stock valued at $12,245,000 after buying an additional 114,903 shares during the period. Diamond Hill Capital Management Inc. lifted its stake in Revvity by 6.3% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 426,899 shares of the company’s stock valued at $41,302,000 after buying an additional 25,233 shares during the period. Finally, Tocqueville Asset Management L.P. bought a new position in shares of Revvity during the 2nd quarter worth approximately $4,791,000. 86.65% of the stock is owned by institutional investors.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.